share_log

Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts

Benzinga ·  Apr 23 14:00

ANI Pharmaceuticals (NASDAQ:ANIP) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings50000
Last 30D10000
1M Ago00000
2M Ago30000
3M Ago10000

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.8, with a high estimate of $83.00 and a low estimate of $72.00. Observing a 9.19% increase, the current average has risen from the previous average price target of $71.25.

price target chart

Interpreting Analyst Ratings: A Closer Look

A clear picture of ANI Pharmaceuticals's perception among...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment